# ‚öîÔ∏è CLINICAL TRIAL DOSSIER

**NCT ID**: NCT00677079  
**Trial Title**: Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  
**Patient ID**: ayesha_001  
**Generated**: 2025-11-14T19:58:03.546940  
**Generated By**: JR2 (Dossier Sidekick)

---

## 1. TRIAL OVERVIEW

**Title**: Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  
**Phase**:   
**Status**: COMPLETED  
**Sponsor**:   
**Estimated Enrollment**: 0  
**Primary Endpoint**: None

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT00677079

---

## 2. ELIGIBILITY ASSESSMENT

**Summary**: 4/6 criteria met

### Eligibility Criteria Table

| Criterion | Status | Confidence | Notes |
|-----------|--------|------------|-------|
| Disease Match | ‚úÖ PASS | 0.90 | Ovarian/gynecologic match: ["primary peritoneal cancer", "advanced epithelial ovarian cancer"] |
| Treatment Line | ‚úÖ PASS | 0.80 | Line match assumed (not explicitly excluded) |
| Biomarker Requirements | ‚úÖ PASS | 1.00 | No biomarker requirements |
| Location (NYC Metro) | ‚úÖ PASS | 0.50 | No location data (assume match) |
| Inclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * Female, age 18 or older;
* Histologically or cytologically confirmed advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (stage III or IV);
* At least one previous... |
| Exclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * Normal clinical laboratory values;
* Any anti-cancer therapy within 21 days prior to study start;
* Any other malignancy within 3 years of study start, except adequately treated carcinoma in situ of... |

---

## 3. STRATEGIC SCENARIOS

### Best Case

**Eligibility Probability**: 66.7%

**Scenario**: All pending biomarker tests return favorable results

**Eligibility Level**: HIGH

### Most Likely

**Eligibility Probability**: 66.7%

**Scenario**: 50% of pending tests pass, some may require additional screening

**Eligibility Level**: MODERATE

### Challenge

**Eligibility Probability**: 66.7%

**Scenario**: Some pending tests fail, may need alternative trials

**Eligibility Level**: LOW

---

## 4. TACTICAL RECOMMENDATIONS

| Action | Lab | Cost | Timeline | Priority | Rationale |
|--------|-----|------|----------|----------|----------|
| Proceed with trial enrollment | N/A | N/A | Immediate | HIGH | All eligibility criteria met |

---

## 5. DRUG MECHANISMS

### Iniparib

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Iniparib

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

---

## 6. LOCATION DETAILS

No location data available.

---

## 7. TIMELINE

**Study Start Date**: 

**Primary Completion Date**: 

---

## 8. FULL ELIGIBILITY TEXT

### Inclusion Criteria

* Female, age 18 or older;
* Histologically or cytologically confirmed advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (stage III or IV);
* At least one previous regimen with platinum/taxane combination therapy and no curative options as determined by their physician (no limit on the number of prior therapies);
* Confirmed BRCA1 or BRCA2 status;
* One or more measurable lesions, at least 10mm in longest diameter by spiral computed tomography (CT) scan or 20mm in longest diameter when measured with conventional techniques (palpation, plain x-ray, CT or magnetic resonance imaging (MRI));
* Karnofsky performance status ‚â•70%;
* Estimated life expectancy of at least 16 weeks.

### Exclusion Criteria

* Normal clinical laboratory values;
* Any anti-cancer therapy within 21 days prior to study start;
* Any other malignancy within 3 years of study start, except adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of the breast, or basal or squamous cell skin cancer;
* Active viral infection including HIV/AIDS, Hepatitis B or Hepatitis C infection;
* Active central nervous system or brain metastases;
* History of seizures or current treatment with anti-epileptic medication;
* Persistent grade 2 or greater toxicities from prior therapy, excluding alopecia.

---

## 9. CONTACT INFORMATION

Contact information not available.

---

## 10. PROVENANCE

**Generated By**: JR2

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION]

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

